Table 3.

Adverse events (any grade, occurring in ≥5% of patients, suspected to be related to study drug), by treatment group

Preferred term, n (%)	1 mg/kg Q2W n=16		3 mg/kg Q2W n=15		10 mg/kg Q2W n=11		3 mg/kg Q4W n=6		5 mg/kg Q4W n=10		All patients N=58
	All	Gr 3/4	All	Gr 3/4	All	Gr 3/4	All	Gr 3/4	All	Gr 3/4	All	Gr 3/4
Total	10 (62.5)	1 (6.3)	10 (66.7)	0	5 (45.5)	1 (9.1)	3 (50.0)	0	6 (60.0)	0	34 (58.6)	2 (3.4)
Fatigue	5 (31.3)	0	2 (13.3)	0	2 (18.2)	0	1 (16.7)	0	3 (30.0)	0	13 (22.4)	0
Diarrhea	4 (25.0)	0	4 (26.7)	0	1 (9.1)	0	0	0	1 (10.0)	0	10 (17.2)	0
Pruritus	3 (18.8)	0	5 (33.3)	0	0	0	0	0	0	0	8 (13.8)	0
Hypothyroidism	2 (12.5)	0	1 (6.7)	0	1 (9.1)	0	0	0	2 (20.0)	0	6 (10.3)	0
Nausea	3 (18.8)	0	1 (6.7)	0	1 (9.1)	0	0	0	1 (10.0)	0	6 (10.3)	0
Decreased appetite	2 (12.5)	0	0	0	1 (9.1)	0	0	0	1 (10.0)	0	4 (6.9)	0
Anemia	2 (12.5)	0	1 (6.7)	0	0	0	0	0	0	0	3 (5.2)	0
Constipation	3 (18.8)	0	0	0	0	0	0	0	0	0	3 (5.2)	0
Dizziness	3 (18.8)	0	0	0	0	0	0	0	0	0	3 (5.2)	0
Dry mouth	1 (6.3)	0	1 (6.7)	0	0	0	0	0	1 (10.0)	0	3 (5.2)	0
Maculopapular rash	1 (6.3)	0	2 (13.3)	0	0	0	0	0	0	0	3 (5.2)	0
Vomiting	2 (12.5)	0	0	0	1 (9.1)	0	0	0	0	0	3 (5.2)	0

Gr, grade; Q2W, once every 2 weeks; Q4W, once every 4 weeks.